The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Utility of circulating tumor DNA in patients with resectable pancreatic cancer using a patient-specific panel: ARTEMIS-PC study.
 
Keiko Kamei
No Relationships to Disclose
 
Taro Shibuki
No Relationships to Disclose
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Makoto Ueno
Honoraria - Asca; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Viatris
Consulting or Advisory Role - Boehringer Ingelheim; Novocure
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Revolution Medicines (Inst); Taiho Pharmaceutical (Inst)
 
Kenji Ikezawa
Speakers' Bureau - AstraZeneca; Chugai Pharma; Eisai; Guardant Health; MSD; Myriad Genetics; Nihon Servier; Taiho Pharmaceutical; TAKATA Pharmaceutical
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Johnson & Johnson/Janssen; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; Jazz Pharmaceuticals; Nihon Medi-Physics; Ohara Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; LabCorp (Inst); Linical (Inst); Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Teiichi Sugiura
No Relationships to Disclose
 
Yoshito Komatsu
No Relationships to Disclose
 
Michiaki Unno
Honoraria - AstraZeneca; Incyte Japan; Miyarisan pharmaceutical; MSD; Taiho Pharmaceutical
Consulting or Advisory Role - Sonire Therapeutics
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kumiko Umemoto
Honoraria - AstraZeneca Japan; Eisai; FINGGAL LINK CO.,LTD.; Guardant Health Japan Corp.; Novartis Pharmaceuticals UK Ltd.; Taiho Pharmaceutical
 
Jacquelyn Reuther
Employment - LabCorp
 
Edward Esplin
Employment - LabCorp
 
Robert Daber
Employment - Invitae Corp. then Labcorp genetics
Leadership - CSO - Invitae Corp.
Patents, Royalties, Other Intellectual Property - Hold Patents, no royalties
 
Emily Westheimer
Employment - Invitae, ForesightDx
Stock and Other Ownership Interests - Invitae
 
Keir Violaceae
Employment - LabCorp
 
Jianhua Zhao
Employment - LabCorp
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Exact Sciences; Guardant Health; Incyte; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)